scholarly journals High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma

2019 ◽  
Author(s):  
He Li ◽  
Xiaocheng Li ◽  
Huapeng Lin ◽  
Jianping Gong
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Malignant Progression ◽  
Ductal Adenocarcinoma

scholarly journals From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma

2020 ◽  
Vol 21 (11) ◽  
pp. 4067 ◽  
Author(s):  
Christopher Montemagno ◽  
Shamir Cassim ◽  
Jacques Pouyssegur ◽  
Alexis Broisat ◽  
Gilles Pagès
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Malignant Progression ◽  
Ductal Adenocarcinoma ◽  
Pancreatic Tumors ◽  
Therapeutic Targeting ◽  
Normal Tissues ◽  
Attractive Candidate ◽  
Rising Incidence ◽  
Resistance To Chemotherapy

Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of all pancreatic tumors, is a highly devastating disease with poor prognosis and rising incidence. The lack of available specific diagnostics tests and the limited treatment opportunities contribute to this pejorative issue. Over the last 10 years, a growing interest pointing towards mesothelin (MSLN) as a promising PDAC-associated antigen has emerged. The limited expression of MSLN in normal tissues (peritoneum, pleura and pericardium) and its overexpression in 80 to 90% of PDAC make it an attractive candidate for therapeutic management of PDAC patients. Moreover, its role in malignant progression related to its involvement in tumor cell proliferation and resistance to chemotherapy has highlighted the relevance of its targeting. Hence, several clinical trials are investigating anti-MSLN efficacy in PDAC. In this review, we provide a general overview of the different roles sustained by MSLN during PDAC progression. Finally, we also summarize the different MSLN-targeted therapies that are currently tested in the clinic.

scholarly journals Aberrant methylation ofReprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma

Cancer ◽  
2006 ◽  
Vol 107 (2) ◽  
pp. 251-257 ◽  
Author(s):  
Norihiro Sato ◽  
Noriyoshi Fukushima ◽  
Hiroyuki Matsubayashi ◽  
Christine A. Iacobuzio-Donahue ◽  
Charles J. Yeo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Genetic Instability ◽  
Poor Prognosis ◽  
Ductal Adenocarcinoma ◽  
Aberrant Methylation

High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC)

Tumor Biology ◽  
2015 ◽  
Vol 36 (12) ◽  
pp. 9189-9199 ◽  
Author(s):  
Chen Gong ◽  
Yixin Zhang ◽  
Yinji Chen ◽  
Haifeng Zhang ◽  
Xiaorong Liu ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Binding Protein ◽  
High Expression ◽  
Ductal Adenocarcinoma

SLC39A1 Contributes to Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma by Activating AMPK Signaling

2021 ◽  
Author(s):  
Hao Yu ◽  
Xiaoping Mei ◽  
Xueming Zhang ◽  
Neng Qian ◽  
Qingjiang Yu ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Protein Expression ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Western Blotting ◽  
Poor Prognosis ◽  
Ductal Adenocarcinoma ◽  
Tumor Type ◽  
Ampk Signaling ◽  
Gemcitabine Resistance ◽  
Mrna And Protein Expression

Abstract Objective: Pancreatic ductal adenocarcinoma (PDAC) serves as a prevailing tumor type with high mortality and poor prognosis. The study aims to explore the mechanism of gemcitabine resistance in PDAC patients. Methods: Immunohistochemistry(IHC)was used to analyze the expression of SLC39A1 in PDAC samples. PDAC cells were culture and transfected with siSLC39A1 and siNC, respectively. Cell proliferation analysis was performed using CCK-8 assay. And qPCR and Western blotting was used to analysis the expression level of SLC39A1 and related signal molecular in cells. Results: IHC results demonstrated that the SLC39A1 expression was significantly up-regulated in the gemcitabine-resistant PDAC samples compared with gemcitabine-sensitive PDAC samples. The treatment of gemcitabine dose-dependently inhibited the viability of the PDAC cells. Meanwhile, the mRNA and protein expression of SLC39A1 were elevated in the gemcitabine-resistant PDAC. The treatment of gemcitabine remarkably decreased viability of PDACs, in which SLC39A1 depletion could reverse this effect. SLC39A1 knockdown could reverse the gemcitabine-induced phosphorylation of AMPK enhanced and gemcitabine-inhibited S6K expression. Conclusion: SLC39A1 contributed to gemcitabine resistance of PDAC by activating AMPK signaling.

Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis

Pancreatology ◽  
2019 ◽  
Vol 19 (3) ◽  
pp. 443-448 ◽  
Author(s):  
Yuki Hashimoto ◽  
Mitsuaki Ishida ◽  
Hironori Ryota ◽  
Tomohisa Yamamoto ◽  
Hisashi Kosaka ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Immunohistochemical Analysis ◽  
Ductal Adenocarcinoma

scholarly journals Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma

2020 ◽  
Vol 123 (1) ◽  
pp. 72-80
Author(s):  
Fabien Robin ◽  
Gaëlle Angenard ◽  
Luis Cano ◽  
Laetitia Courtin-Tanguy ◽  
Elodie Gaignard ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Molecular Profiling ◽  
Ductal Adenocarcinoma

scholarly journals High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma

2020 ◽  
Vol 11 (8) ◽  
pp. 2213-2221
Author(s):  
Ming Cui ◽  
Lei You ◽  
Bang Zheng ◽  
Xinmei Huang ◽  
Qiaofei Liu ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Immunoglobulin G ◽  
Poor Prognosis ◽  
High Expression ◽  
Ductal Adenocarcinoma

scholarly journals Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Tao Sun ◽  
Xiangyu Kong ◽  
Yiqi Du ◽  
Zhaoshen Li
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Vital Role ◽  
High Rate ◽  
Ductal Adenocarcinoma ◽  
Clinical Implications ◽  
Circulating Mirnas ◽  
Current Review ◽  
Wide Range

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality and poor prognosis. Numerous studies have proved that microRNA (miRNA) may play a vital role in a wide range of malignancies, including PDAC, and dysregulated miRNAs, including circulating miRNAs, are associated with PDAC proliferation, invasion, chemosensitivity, and radiosensitivity, as well as prognosis. Greater understanding of the roles of miRNAs in PDAC could provide insights into this disease and identify potential diagnostic markers and therapeutic targets. The current review focuses on recent advances with respect to the roles of miRNAs in PDAC and their practical value.

Sign in / Sign up

Export Citation Format

Share Document